卵巢切除股骨骨折大鼠骨愈合中降钙素的作用

背景：降钙素可活化腺苷酸环化酶蛋白激酶A通路及磷脂酶C通路,抑制破骨细胞的活性,可能治疗骨质疏松性骨折。 目的：观察降钙素对去卵巢大鼠股骨骨折愈合的作用。 方法：构建双侧卵巢切除骨质疏松右股骨骨折SD大鼠模型,然后分别皮下注射生理盐水和降钙素(16 IU/kg),隔日1次,于骨折后3周和6周测量右股骨行骨密度,苏木精-伊红及抗酒石酸酸性磷酸酶染色,骨形态发生蛋白2及血管内皮生长因子免疫组化染色。 结果与结论：骨折后给予降钙素治疗的大鼠抗酒石酸酸性磷酸酶染色阳性细胞积分吸光度值较生理盐水治疗的大鼠显著减少(P < 0.05)。骨折后3周,两组骨折线均较清晰,骨痂体积无明显差别,骨折愈合以软骨内化骨过程为主,骨密度无显著性差异(P > 0.05)。骨折后6周,两组骨折线较模糊,骨痂体积无差别,骨小梁排列较有序,用药组股骨骨密度较对照组升高(P < 0.05)。两组在骨折后3周和6周的骨形态发生蛋白2及血管内皮生长因子差异无显著性意义(P > 0.05)。证实降钙素可以抑制去卵巢大鼠骨折部位破骨细胞活性,但无明显促进大鼠股骨骨折愈合的作用。     

糖尿病性骨质疏松模型雌激素、一氧化氮及转化生长因子β1的变化

背景：糖尿病和卵巢去势是骨质疏松发生的两大主要原因,均会出现一氧化氮和转化生长因子β1的变化。 目的：探讨雌激素、一氧化氮、转化生长因子β1在糖尿病性骨质疏松模型中的变化及意义。 方法：采用链脲佐菌素诱导制备糖尿病大鼠模型,于造模后4,8,12,16周,进行骨密度检测,并应用放免法检测血清雌激素水平,硝酸还原酶法检测血清一氧化氮水平,ELISA法检测血清转化生长因子β1水平,免疫组织化学法检测骨中转化生长因子β1水平。 结果与结论：随着链脲佐菌素诱导时间的延长,糖尿病大鼠股骨骨密度逐渐降低(P < 0.05或P < 0.01);血清一氧化氮水平逐渐降低(P < 0.05或P < 0.01);血清转化生长因子β1水平逐渐升高(P < 0.01);血清雌激素水平轻度降低,与同时间点正常大鼠比较差异无显著性意义(P > 0.05)。免疫组织化学结果显示转化生长因子β1主要表达于成骨细胞的胞浆中,其阳性表达随链脲佐菌素诱导时间的延长逐渐下降(P < 0.01)。说明糖尿病大鼠血清一氧化氮水平和骨组织中转化生长因子β1水平的变化导致了骨吸收增加,骨形成减少,使骨密度降低,参与了糖尿病性骨质疏松的发生。     

阿仑膦酸钠可抑制骨质疏松性骨折的愈合

背景：阿仑膦酸钠作为治疗骨质疏松症的首选药物已被临床广泛应用。 目的：观察阿仑膦酸钠对骨质疏松性骨折大鼠股骨干骨折愈合的影响。 方法：将SD大鼠随机分成3组：假手术组,模型组和阿仑膦酸钠组。模型组及阿仑膦酸钠组于卵巢切除后4周进行右股骨干中段横行骨折,克氏针固定。阿仑膦酸钠组建模后皮下注射阿仑膦酸钠。 结果与结论：骨折造模后3及6周,阿仑膦酸钠组右股骨整体骨密度和远段骨密度高于模型组(P < 0.01),与模型组相比,阿仑膦酸钠组骨折端骨痂体积大、骨痂数量多,软骨性骨痂向骨性骨痂转换过程延迟,骨折愈合过程减慢,破骨细胞数量显著降低(P < 0.05)。结果证实,阿仑膦酸钠对大鼠骨质疏松性骨折愈合过程有抑制作用,其机制可能与阿仑膦酸钠抑制破骨细胞活性使骨痂钙化过程减慢有关。     

短期中等强度跑台运动对雄性高脂血症大鼠骨密度的影响

背景：高脂血症可导致大鼠骨质疏松,适量运动可增加骨密度,但短期运动对高脂血症导致骨质疏松的雄性动物骨密度的影响尚不清楚。 目的：探讨短期中等强度跑台运动对雄性高脂血症大鼠骨密度的影响。 方法：将26只SD雄性大鼠随机分为正常对照组(n=8)、高脂血症组(n=9)、运动干预组(n=9)。正常对照组喂饲普通饲料;其他两组喂饲高脂饲料建立大鼠高脂血症模型,持续4周。运动干预组大鼠进行跑台训练,每周训练5 d,共4周,每天强度为：第1周15 min,速度15 m/min;第2周20 min,速度15 m/min;后2周20 min,速度20 m/min,跑台坡度均为0°。实验结束后处死大鼠,取其右侧股骨检测骨密度、胫骨观察骨形态变化,测定血浆碱性磷酸酶活性和钙磷含量。 结果与结论：与正常对照组比较,高脂血症组股骨远端骨密度显著降低(P < 0.05),胫骨近端骨小梁排列稀疏变薄,间隙增宽,髓腔内有大量脂肪细胞浸润或融合成空泡,血浆碱性磷酸酶明显增加(P < 0.01)。与高脂血症组比较,运动干预组股骨远端骨密度显著增加(P < 0.05),经体质量校正后股骨全骨密度增加(P < 0.05),胫骨近端骨小梁排列致密整齐,小梁间距小,血浆碱性磷酸酶增加(P < 0.01)。血浆钙磷含量各组间差异无显著性意义。实验结果说明短期中等强度跑台运动增加高脂血症雄性大鼠骨密度。     

仙灵骨葆对骨质疏松性骨折骨痂血管形成的影响

背景：骨质疏松对骨折愈合早期的影响尚存争议,仙灵骨葆对骨质疏松性骨折愈合的影响及其机制尚有待深入研究。 目的：观察骨质疏松对大鼠股骨干骨折愈合的影响,以及仙灵骨葆对骨质疏松性骨折愈合的作用。 方法：将50只雌性12周龄Sprague-Dawley大鼠随机分成5组：假手术组、骨折组、去卵巢组、去卵巢+骨折组及治疗组,后3组切除大鼠双侧卵巢制备去卵巢模型,骨折模型于去卵巢后4周制备,为股骨干中段横行骨折。治疗组在去卵巢及骨折基础上灌胃给予仙灵骨葆250 mg/(kg•d)。给药3周,取去卵巢+骨折组、骨折组和治疗组大鼠骨折侧标本行X射线摄像仪摄片后,测量其骨密度,苏木精-伊红染色观察骨痂组织的病理学改变并计数血管,免疫组织化学染色检测骨痂组织骨形态发生蛋白2的表达。 结果与结论：去卵巢处理后大鼠的骨密度、计算机X射线摄像仪摄片评分显著降低(P < 0.05),仙灵骨葆可在一定程度上提高去卵巢后骨折大鼠的骨密度及X射线摄像仪摄片评分,但差异无显著性意义(P > 0.05);仙灵骨葆可提高去卵巢后骨折大鼠骨痂组织的血管数量(P < 0.05),但对骨形态发生蛋白2的表达无影响。提示,去卵巢后大鼠骨折早期愈合过程延迟,仙灵骨葆可促进骨质疏松大鼠骨折愈合早期血管的形成。     

激素性股骨头坏死模型兔骨组织病理及功能变化

背景：目前对激素性股骨头坏死的研究均未涉及成骨细胞、破骨细胞变化所引起的细胞功能改变。 目的：观察激素性股骨头坏死模型兔骨代谢指标及骨组织病理学变化。 方法：将32只新西兰大白兔随机等分为正常组和模型组。模型组臀肌注射醋酸氢化可的松注射液8.0 mg/kg,每周2次,持续8周,建立激素性股骨头坏死兔模型;正常组注射等量的生理盐水。 结果与结论：与正常组比较,模型组从第2周开始血清钙、磷显著降低(P < 0.05),而抗酒石酸酸性磷酸酶活性显著升高 (P < 0.05);从第4周开始,模型组骨特异性碱性磷酸酶水平升高,骨钙素水平降低(P < 0.05);模型组骨特异性碱性磷酸酶水平至第8周有所下降。与正常组比较,模型组股骨转子骨密度从第2周开始降低(P < 0.05),股骨头骨密度从第4周开始降低(P < 0.05);成骨细胞数从第4周开始明显降低,破骨细胞数从第4周开始明显升高(P < 0.05)。提示激素可通过损伤骨组织细胞引起骨塑形及骨重建的破坏,造成骨矿物盐的丢失,引起激素性股骨头坏死的发生。     

补肾健脾方干预去势大鼠骨骼肌caspase-3和caspase-8的表达

背景：骨骼肌与骨质疏松症关系密切,导致其衰退的主要原因是细胞的凋亡,这种凋亡可能是Caspase家族蛋白所介导的。 目的：探讨补肾健脾方对去势大鼠骨骼肌caspase-3和 caspase-8调控作用。 方法：SD大鼠48只等随机分为对照组、模型组、中药组、西药组,后3组大鼠摘除双侧卵巢建立骨质疏松模型,对照组仅切除周围少量脂肪组织。造模2周后,中药组给予补肾健脾方(2.979 g/kg)灌胃,西药组给予戊酸雌二醇片(0.104 mg/kg)灌胃,模型组和对照组给予蒸馏水灌胃,1次/d。 结果与结论：①干预12周后,双能X线骨密度仪测量发现,相比于对照组,模型组大鼠左侧股骨的骨密度值和骨矿含量均明显降低(P < 0.01);而中药组和西药组的骨密度值均高于模型组(P < 0.05),且2组骨密度值和骨矿含量接近(P > 0.05)。②酶标免疫分析显示,与对照组相比,模型组骨骼肌中Caspase-3和 Caspase-8表达水平明显上升(P < 0.05)。中药能显著降低大鼠骨骼肌中Caspase-3的表达水平(P < 0.05),而西药能显著减低Caspase-8表达水平(P < 0.05)。③说明补肾健脾方对卵巢切除所致的骨质疏松症有明显的治疗作用,能明显提高骨密度,而且能显著减低Caspase-3的水平,但不能显著减低Caspase-8水平,显示补肾健脾方不是通过死亡受体途径去抑制细胞凋亡的。     

葛根异黄酮联合维生素D防治骨质疏松的协同效应

背景:葛根异黄酮具有类雌二醇结构特征,对去卵巢大鼠的骨质丢失和骨量的减少有一定的抑制作用。但也有报道其对去卵巢大鼠骨质疏松的防治效果较弱且单独使用效果不明显。 目的：观察葛根异黄酮与维生素D联合对去卵巢大鼠骨质疏松的作用。 方法：将81只3月龄雌性SD大鼠随机分为9组: 除假手术组外其他各组均行双侧卵巢摘除造模。低、中、高剂量TIP组,VitD组,低、中、高剂量联合组在去卵巢基础上分别灌胃给予相应剂量的葛根异黄酮和（或）维生素D;模型组和假手术组不给予药物治疗。给药3个月,计算大鼠子宫系数;测定大鼠血清碱性磷酸酶、血钙、血磷、骨钙素及血清雌二醇水平;检测大鼠股骨骨密度。 结果与结论：与模型组比较,中、高剂量TIP组,低、中、高剂量联合组大鼠子宫系数、雌二醇水平明显增高(P < 0.05),血清碱性磷酸酶、骨钙素水平明显降低(P < 0.05),股骨中心及远心骨密度均明显增加(P < 0.05),均以高剂量联合组作用效果最明显。且在子宫系数,雌二醇、血清碱性磷酸酶、骨钙素水平及股骨远心端骨密度方面,葛根异黄酮和维生素D均表现为协同作用。在血钙、血磷方面,葛根异黄酮和(或)维生素D的作用不明显。说明葛根异黄酮和维生素D联合使用对去卵巢大鼠骨质疏松的防治有协同效应。     

大豆异黄酮干预去势大鼠骨密度及成骨细胞雌激素受体α的表达

背景：大豆异黄酮是一类植物雌激素,对绝经后骨质疏松症治疗具有重要意义。 目的：进一步验证大豆异黄酮对去势大鼠骨密度和成骨细胞雌激素受体α表达的影响。 方法：将12月龄去势雌性SD大鼠随机分为3组,大豆异黄酮组和对照组大鼠摘除双侧卵巢,假手术组只进行手术入路,不切除卵巢。大豆异黄酮组切除卵巢后,每日灌胃大豆异黄酮,连续40 d。对照组喂等量生理盐水。 结果与结论：喂饲40 d后对照组大鼠左侧股骨骨密度值显著低于假手术组(P < 0.05),提示骨质疏松模型成功。大豆异黄酮组大鼠左侧股骨骨密度高于对照组(P < 0.05);大豆异黄酮组雌激素受体α的表达量高于对照组(P < 0.05)。提示大豆异黄酮可增加去势大鼠骨密度,提高去势大鼠成骨细胞雌激素受体α的表达,促进成骨细胞增殖。     

唑来膦酸对髋关节置换后假体柄周围骨丢失的预防效果

背景：无论是股骨侧还是髋臼侧在髋关节置换后1年内均会出现不同程度的骨丢失,对假体的长期稳定性和骨强度造成严重影响。因而减少全髋关节置换后假体柄周围骨丢失量对延长假体使用时间、预防假体周围骨折具有重要意义。 目的：观察分析唑来膦酸对髋关节置换后假体柄周围骨丢失的预防效果。 方法：对照组患者不给予,两组其余用药相同。对两组置换前和置换后1年的髋部骨密度变化进行测量;观察两组置换前、用药后3 d和用药后1年的血清钙、磷水平及碱性磷酸酶活性变化;对观察组患者用药期间出现的不良反应进行记录。  结果与结论：置换后1年两组患者股骨假体周围的平均骨密度均显著下降,与置换前比较差异有显著性意义(P < 0.05)。置换后1年观察组患者的平均骨密度显著高于对照组(P < 0.05)。用药后3 d两组患者的钙、磷水平均较置换前显著下降,差异均有显著性意义(P < 0.05)。用药后1年钙、磷水平维持在置换前水平。置换后短期内两组患者的碱性磷酸酶活性均稍微下降,但与置换前比较差异无显著性意义(P > 0.05)。用药后1年,观察组患者的碱性磷酸酶活性较低,与置换前、对照组比较差异均有显著性意义(P < 0.05)。用药后1年,对照组患者的碱性磷酸酶活性与置换前差异无显著性意义(P > 0.05)。用药两三天内观察组有9例患者出现不同程度的肌肉酸痛和发热,给予乙酰氨基酚后症状得到缓解。提示全髋关节置换后给予唑来膦酸注射液能够有效预防患者置换后早期假体柄周围骨丢失,但是置换后1周内可能会出现发热的症状,因此建议在置换完成1周后给予患者唑来膦酸注射液,若出现发热等症状,可给予乙酰氨基酚进行缓解。 中国组织工程研究杂志出版内容重点：人工关节;骨植入物;脊柱;骨折;内固定;数字化骨科;组织工程     

定量CT测定骨矿物含量的双能量方法

骨质疏松症最早显示在椎骨小梁骨的变化上。用定量ＣＴ测量椎骨小梁骨矿物质含量，可对该病进行早期诊断。双能量方法可分离出脂肪影响。提高测试精度。对两种双能量方法定量地分析了它们的系统误差和随机误差，并与单能量方法的误差对照。完成了２０个临床病例的试验。单能量ＣＴ系统误差较大，双能量ＣＴ随机误差较大，但若ＣＴ机的测试误差控制在正常范围内，则双能量ＣＴ的总误差明显地小于单能量ＣＴ的总误差。故认为双能量方法     

椎体骨微结构参数与椎弓根螺钉固定强度的相关性

目的 测量不同骨密度（bone mineral density, BMD）条件下椎体松质骨显微结构参数,并与椎弓根螺钉拔出力作相关性分析,以了解与螺钉稳定性相关的骨显微结构参数,进一步明确螺钉松动的原因。方法 采用新鲜尸体脊柱标本,根据BMD检测结果,按临床诊断标准分为骨质正常、骨量减少、骨质疏松和重度骨质疏松4个水平。然后植入椎弓根螺钉,进行螺钉轴向拔出实验,测定最大拔出力（maximum pullout strength, MPS）。收集螺钉拔出实验后椎体标本,在椎体中央部钻取松质骨柱状样本,对样本进行显微CT扫描,获取椎体松质骨显微结构参数,并进行各项指标的不同BMD水平间的比较分析,在了解这些指标随骨质疏松程度加重的变化规律的基础上,再对骨显微结构参数与所对应的螺钉MPS开展相关性分析。结果BMD水平从正常下降到重度疏松程度,MPS随之显著性下降。随BMD水平的依梯次下降,即骨质疏松程度进行性加重,椎体松质骨显微结构参数发生相应明显变化,存在BMD水平间的显著性差异。广泛的相关性存在于BMD、显微CT参数和螺钉MPS指标之间。其中,螺钉MPS与显微CT扫描所得的骨体积分数（BV/TV）、骨小梁厚度（Tb.Th）和小梁间隙（Tb.Sp）呈高度相关性。结论 随BMD下降,骨组织会同时发生质的退变;螺钉MPS与部分骨显微结构参数高度相关。     

骨密度定量检测方法及性能比较

随着人口老龄化,骨质疏松症已成为世界各国关注的公共健康问题.目前,骨密度的定量检测是诊断骨质疏松症的最好方法,正日益受到医学临床重视.综述了现有临床采用的X线照相或X光片密度测量、单光子和单能X线吸收测量法、双能光子和双能X线吸收法、定量CT或定量超声或定量磁共振成像（MRI）技术等主要的骨密度定量检测方法的原理,并分析比较其优缺点.     

老龄引起骨质疏松的模拟

研究老龄对骨质疏松的影响。应用带有力学调控系统的各向异性骨再造模型结合有限元法进行数值模拟。结果表明进入老年期后,由于肌肉力量的降低和活动量的减少而导致外载荷下降,骨量相对于峰值丢失25%以上,产生骨质疏松。力学因素可导致老年性骨质疏松,表明力学因素在预防和治疗骨质疏松起重要作用。     

Identification of the risk factors for osteoporosis among postmenopausal women

ObjectivesThe aim of this study was to determine the effect of different durations of menopause at the time of bone mineral density (BMD) measurement and of different age at menopause intervals on the prevalence of osteopenia and osteoporosis among untreated postmenopausal women. We also assessed related factors leading to low BMD.MethodsA total of 2769 postmenopausal women who had not taken any anti-osteoporosis treatment and/or hormone replacement therapy were divided into three groups according to duration of menopause at the time of BMD measurement. The women were also evaluated in four different age groups according to their age at menopause onset. Multinomial logistic regression analysis was used to determine related factors leading to low BMD. Investigated parameters include demographic characteristics, plasma glucose, lipids, and lipoproteins.ResultsAccording to World Health Organization (WHO) criteria, among 2769 patients, 449 (16.2%) were identified as having osteoporosis, 1085 (39.2%) as having osteopenia, and 1235 (44.6%) as having normal BMD. Osteoporosis was determined in 10.6% and 16.2% of women with menopause duration of 0–3 years and 4–7 years, respectively, whereas this rate was 31.9% in women with menopause duration of over 7 years (p = 0.001). The percentages for osteopenia remained constant among the three different menopause durations (0–3 years: 37.2%, 4-7 years: 42.1%, and >7 years: 40.9%). Thirty percent of women with age at onset of <40 years were osteoporotic. However, the percentages of women with osteoporosis among the other age groups were similar (40–46 years: 18.3%, 47–52 years: 14.1%, and >52 years: 15.4%). The percentages for osteopenia remained relatively constant among the four age groups (36.7, 40, 39.1 and 39%). According to the multinomial logistic regression analysis, duration of menopause at the time of BMD test and parity were positively correlated with both osteoporosis and osteopenia, while glucose level was negatively correlated with both osteoporosis and osteopenia. Age at menopause was negatively correlated only for osteoporosis. Low-density lipoprotein cholesterol (LDL-c) level may be accepted as a clinically significant factor for osteopenia (OR: 1.01; CI_95%: 1.00–1.02). No differences were determined in the prevalence of osteopenia and osteoporosis in women with menopause duration of >7 years when evaluated according to the four menopause age groups as described before (p = 0.74). Contribution to the regression model was 0.8% by age at menopause, 5.6% by menopause duration at time of BMD measurement, 5.8% by both factors.ConclusionAccording to our results, osteoporosis is related more to the duration of menopause at the time of BMD measurement rather than the age at menopause among untreated postmenopausal women. High parity was determined as another risk factor for low BMD.     

Calcaneal Quantitative Ultrasound as a Determinant of Bone Health Status: What Properties of Bone Does It Reflect?

Quantitative ultrasound (QUS) has emerged as a convenient and popular screening tool for osteoporosis. This review aimed to provide basic information on the principle of QUS measurement and discuss the properties of bone reflected by QUS indices. QUS employed high frequency sound waves generated by the device to determine bone health status in humans. In vitro studies showed that QUS indices were significantly associated with bone mineral density (BMD), bone microarchitecture and mechanical parameters. In humans, QUS indices were found to be associated with BMD as well. In addition, QUS could discriminate subjects with and without fracture history and predict risk for future fracture. In conclusion, QUS is able to reflect bone quality and should be used in the screening of osteoporosis, especially in developing countries where dual-X-ray absorptiometry devices are less accessible to the general population.     

双膦酸盐药物长期应用对显微损伤和骨力学性能的影响

双膦酸盐类药物作为治疗骨质疏松的一线药物,可以通过降低骨转换来增加骨密度,防止骨折的发生,在临床已经有较长期应用。最近研究表明,双膦酸盐类药物在抑制骨重建的同时,会影响显微损伤的修复,导致显微损伤的积聚和骨质量的下降,进而降低骨的韧性,削弱骨的力学性能。已有临床报告指出,骨质疏松病人使用双膦酸盐后有可能发生非创伤性骨折。本文综述了双膦酸盐类药物对骨显微损伤和骨力学性能的影响。     

骨质疏松性骨力学性能的预测研究

骨力学性能是发现与评价骨质疏松重要而直接的参考指标,但临床目前尚难对骨质疏松患者的骨力学性能做出非侵入性的直接评估。因此,研究通过间接手段进行骨力学性能的预测已成为骨质疏松研究领域的一个重要课题,并具有重要的临床应用价值。本文综述了对骨质疏松性骨力学性能进行预测的研究进展,并展望了该领域研究的发展前景。     

Influence of Obesity on Bone Mineral Density in Postmenopausal Asthma Patients Undergoing Treatment with Inhaled Corticosteroids

OBJECTIVES:

The etiology of osteoporosis in asthma is complex as various factors contribute to its pathogenesis. The purpose of our study was to investigate the effects of obesity and inhaled steroids, as well as the severity and duration of asthma, on osteoporosis in postmenopausal asthma patients as compared to healthy controls.

METHODS:

A total of 46 patients with asthma and 60 healthy female controls, all postmenopausal, were enrolled in our study. Bone mineral density was assessed at the lumbar spine and hip using a Lunar DPX-L densitometer.

RESULTS:

Bone mineral density (BMD) scores were comparable between the asthmatic and control groups, with average scores of 0.95 ± 0.29 and 0.88 ± 0.14 g/cm², respectively. Likewise, osteoporosis was diagnosed in a similar percentage of patients in the asthmatic (39.1%) and control (43.3%) groups. Bone fracture was identified in four patients with asthma (8.6%) and in six patients from the control group (10%). We could not detect any relationship between BMD and duration of asthma, asthma severity, inhaled steroids or body mass index (BMI). There was no difference between the two groups with respect to age or years since menopause. Although asthma patients were more likely to be overweight and presented higher BMD scores on average than the control subjects, these differences were not statistically significant.

CONCLUSIONS:

There is a slight positive protective effect of high BMI against osteoporosis in asthma patients, but this effect is overcome by time and menopause status. Therefore, the protective effect of obesity against osteoporosis in asthma patients seems to not be significant.     

Osteocalcin und Knochenhistologie bei Osteoporose

Summary The decoupling of bone formation and bone resorption causes an insidious bone loss that is responsible for the negative skeletal balance in the frequent form of low turnover osteoporosis. The reduction of bone formation can hardly be verified by clinical methods.Osteocalcin, a non-collagenous bone protein, has proved to be a useful new indicator of bone formation. To establish its predictable value, plasma levels of osteocalcin were compared to conventional serological data of bone turnover and to histomorphometric parameters of iliac crest trabecular bone.In cases of osteoporosis with normal bone turnover activity (as confirmed by histomorphometry) no differences were observed in any of our laboratory data including osteocalcin. However, there was a significant lower mean serum level of osteocalcin in a group of patients with histomorphometrically proven low turnover osteoporosis in comparison to those with normal bone turnover. Serum levels of osteocalcin below 2.0 ng/ml seem to indicate a low turnover in the individual case of osteoporosis while this is unlikely when serum levels above 6.0 ng/ml are measured (according to our RIA).

---

Abkürzungsverzeichnis OC Osteocalcin - TBV trabekuläres Knochenvolumen - ROV relatives Osteoidvolumen - ROS relative Osteoidoberfläche - RRS relative Resorptionsoberfläche